Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
Until recently, approved treatments for Alzheimer’s disease (AD) primarily consisted of approved procognitive symptomatic drugs (e.g., donepezil, memantine), as well as off-label antidepressants and atypical antipsychotics, to address behavioral and neuropsychiatric symptoms. However, the AD treatment landscape is shifting with the recent launches of DMTs, including Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), for early AD. Additionally, Lundbeck / Otsuka’s Rexulti became the first drug to approved by the FDA for agitation in AD. Numerous potential DMTs (e.g., Eisai / Biogen’s subcutaneous lecanemab, Eli Lilly’s remternetug, Roche’s trontinemab, Novo Nordisk’s semaglutide) and emerging neuropsychiatric treatments (e.g., Axsome’s Auvelity, Karuna / BMS’s Cobenfy) are in the pipeline. Established and emerging players must understand today’s treatment landscape and patient journey to optimize future uptake and competitive positioning.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AD patients?
- How have Adlarity and Rexulti been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of AD patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What percentage of AD patients are treated with monotherapy versus combination therapy? What are the most used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Markets covered: United States
Key drugs: Adlarity, donepezil, galantamine, memantine IR, Namenda XR, Namzaric, rivastigmine, rivastigmine patch, atypical antipsychotics, Rexulti, Nuplazid, antidepressants
